Emdogain – Available in the USA again

The FDA has reinspected the BIORA facility and is satisfied with the improvements made. Because the focus of the observations was on the maintenance of quality system documentation and procedures, changes to Straumann® Emdogain, Straumann® PrefGel and Straumann® BoneCeramic were not needed in order to resolve the FDA issues.
Straumann has changed the delivery mechanism of Straumann® PrefGel from a pipette to a syringe, which will help to ensure easier, more effective handling of the root conditioner.

Leave a Reply

Your email address will not be published.